

Ein cyf/Our ref: AWMSG to May 2013

Gofynnwch am/Please ask for: Sue Beach

Rhif Ffôn /Telephone: 01554 783462

Ffacs/Facsimile:

E-bost/E-mail: sue.beach@wales.nhs.uk

Dr Carol Llewellyn-Jones
Glangwili General Hospital
Dolgwili Road, Carmarthen,
Carmarthenshire, SA31 2AF
Tel: 01267 235151

Dr Carol Llewellyn-Jones
Ysbyty Cyffredinol Glangwili
Heol Dolgwili, Caerfyrddin
Sir Gaerfyrddin, SA31 2AF
Rhif Ffôn: 01267 235151

29 August 2013

BY EMAIL

Page 1 of 2

**TO: All prescribers
County lead pharmacists
Assistant Director of Nursing (Practice)
Hywel Dda Health Board global email**

Dear Colleague

The appraisals listed below have been published by the All Wales Medicines Strategy Group (AWMSG). They have been assessed for local implementation and their place in therapy established as described.

Please ensure that your teams are fully aware of this information.

In accordance with the provisions of Welsh Ministerial Letter ML/009 /09 (see [EH/ML/009/09](#), 19.3.09), these drugs are being added to the Health Board's formulary, <http://hywelddahb.inform.wales.nhs.uk/>, and will be available for prescribing in accordance with the guidance.

Please ensure that the appropriate audit forms are completed for all initiations on these therapies in the next 12 months. You will find the audit forms on the [Clinical Systems \(NICE / TA AWMSG appraisal audits\)](#) pages of the Health Board's Intranet: <http://howis.wales.nhs.uk/sitesplus/862/page/43199>

Pharmacy has been notified of the guidance and you should be aware that prescriptions that fall outside the recommendations of AWMSG guidance will be discussed with prescribers before dispensing. Please note that failure to complete the appropriate audit form may result in a delay in dispensing.

AWMSG 0213 Vildagliptin (Galvus):

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1531>

DPP-4 inhibitors (Gliptins) as a group have been reviewed, vildagliptin will be available for patients who are unable to tolerate or have contra-indications to 1st or 2nd line gliptins.

AWMSG 4312 Argatroban (Exembol):

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1405>

Argatroban has been approved for use following the Cardiff & Vale Protocol.

Pencadlys Bwrdd Iechyd Hywel Dda
Llys Myrddin, Lôn Winch, Hwlfordd,
Sir Benfro, SA61 1SB
Rhif Ffôn: (01437) 771220
Rhif Ffacs: (01437) 771222

Hywel Dda Health Board Headquarters
Merlins Court, Winch Lane, Haverfordwest,
Pembrokeshire, SA61 1SB
Tel Nr: (01437) 771220
Fax Nr: (01437) 771222

Cadeirydd / Chairman
Mr Chris Martin
Prif Weithredwr / Chief Executive
Yr Athro/Professor Trevor Purt

Bwrdd Iechyd Hywel Dda yw enw gweithredol Bwrdd Iechyd Lleol Hywel Dda
Hywel Dda Health Board is the operational name of Hywel Dda Local Health Board

Mae Bwrdd Iechyd Hywel Dda yn amgylchedd di-fwg Hywel Dda Health Board operates a smoke free environment

AWMSG 0513 Linagliptin (Trajenta®):

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1667>

DPP-4 inhibitors (Gliptins) as a group have been reviewed, linagliptin is recommended for 2nd line use. Where there is a trend to renal impairment linagliptin can be considered.

If you have any questions relating to the guidance or this process, please contact Sue Beach, Lead Clinical Development Pharmacist, on 01554 783084; email sue.beach@wales.nhs.uk.



Dr Carol Llewellyn-Jones
Consultant Physician
Chairman, Medicines Management Group
AMD Carmarthenshire